Capricorn Fund Managers Ltd Invests $144,000 in MediciNova, Inc. (NASDAQ:MNOV)

Capricorn Fund Managers Ltd bought a new position in shares of MediciNova, Inc. (NASDAQ:MNOV – Get Rating) in the fourth quarter, Holdings Channel reports. The fund bought 53,700 shares of the biopharmaceutical company’s stock, valued at approximately $144,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Marshall Wace LLP acquired a new position in MediciNova in the first quarter valued at about $54,000. Buckingham Strategic Partners bought a new stake in shares of MediciNova during the fourth quarter worth about $27,000. Qube Research & Technologies Ltd bought a new stake in shares of MediciNova during the fourth quarter worth about $37,000. UBS Group AG grew its holdings in shares of MediciNova by 96.0% during the third quarter. UBS Group AG now owns 19,272 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 9,437 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of MediciNova by 132.3% during the third quarter. Dimensional Fund Advisors LP now owns 54,532 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 31,062 shares during the last quarter. 15.57% of the stock is owned by institutional investors.

Separately, StockNews.com began coverage on MediciNova in a report on Tuesday. They issued a “hold” rating on the stock.

Shares of NASDAQ:MNOV traded up $0.01 during trading on Wednesday, reaching $2.39. 111,275 shares of the stock were exchanged, compared to its average volume of 80,824. The stock has a fifty day moving average of $2.67 and a two-hundred day moving average of $2.71. MediciNova, Inc. has a 1-year low of $2.09 and a 1-year high of $5.09.

MediciNova (NASDAQ:MNOV – Get Rating) last posted its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. Equities research analysts anticipate that MediciNova, Inc. will post -0.27 earnings per share for the current fiscal year.

About MediciNova (Get Rating)

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.

Recommended Stories